Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 Jan. 23];9(6):s660. Available from: https://skin.dermsquared.com/skin/article/view/3833